Caregivers should ask the neurologist for the exact dementia type and stage, which treatments fit that stage, and what to monitor, plan, and arrange next. Dementia means ongoing loss of memory, thinking, and daily skills that interferes with independent life. Bring a short written list, take notes, and ask who to call between visits. A clear diagnosis guides medicines, safety steps, legal papers, and support services.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What type of dementia is it and how was it decided?
- Do Alzheimer's drugs fit this stage?
- What symptoms, safety steps, and follow-up should we expect?
- What papers, help, and research options should we line up now?
What type of dementia is it and how was it decided?
Ask which specific type was diagnosed — Alzheimer's, Lewy body, vascular, or another cause — and what stage was assigned. The Alzheimer's Association says different dementias differ in symptoms and care, so the label shapes daily help (Alzheimer's Association Just Diagnosed guidance). Ask which tests set the diagnosis and what each test showed.
Evaluation often uses patient and family history, daily-function and behavior review, plus biomarkers such as brain imaging and spinal-fluid proteins. Ask what else could mimic or worsen memory loss. Sleep problems, mood changes, medicines, thyroid issues, vitamin gaps, and other brain conditions can affect thinking and function.
Do Alzheimer's drugs fit this stage?
Ask whether the stage is mild cognitive impairment or mild dementia with confirmed amyloid. Science reporting on the FDA approvals notes lecanemab, approved July 2023, and donanemab, approved July 2024, are indicated only for early symptomatic disease, not moderate or advanced dementia (Science reporting on the FDA approvals). Ask about likely benefit and brain-bleed and swelling risks.
Trials showed about 25–30% slower decline over 18 months, while amyloid-related imaging abnormalities occurred in roughly 21–37% of treated participants. Ask who is not a good candidate and what monitoring is required. The same reporting frames these drugs as a prescribing dilemma, so ask about scans, side-effect warning signs, other medicines, and when to stop.
What symptoms, safety steps, and follow-up should we expect?
Ask what symptoms and pace of decline are typical for this type and what can be treated. Most dementias cannot be cured, but symptoms, mood, sleep, medicines, and coexisting conditions can be managed. Ask how often the neurologist will review memory, behavior, daily function, medicines, mood, and sleep.
Ask what change should trigger a sooner call, such as a fall, new confusion, agitation, or lost daily skills. Ask when driving must be reassessed. American Academy of Neurology guidance states patients with mild dementia face substantially higher crash risk and should strongly consider stopping driving, with severity and fitness reassessed about every 6 months (American Academy of Neurology guidance).
What papers, help, and research options should we line up now?
Ask which legal, financial, and advance-care papers to complete while decision capacity remains. The list often includes: Ask for referrals to local support and research.
Options can include an Alzheimer's Disease Research Center, local Alzheimer's Association resources and 24/7 helpline, and checks for clinical-trial eligibility. Ask the office to place the referrals before you leave.
- durable power of attorney for finances
- health-care directive and care preferences
- permission for the doctor and lawyer to speak with the caregiver
